Replimune Group, INC Form 4 insider transactions

Emily Luisa Hill, CFO of Replimune Group, sold 8,938 shares of common stock on August 16, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Konstantinos Xynos, Chief Medical Officer of Replimune Group, sold 15,881 shares of common stock at an average price of $7.50 per share under a pre-arranged trading plan.

Christopher Sarchi, Chief Commercial Officer of Replimune Group, sold 2,218 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Andrew Schwendenman, Chief Accounting Officer of Replimune Group, Inc., sold 2,298 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Colin Love, Chief Operating Officer of Replimune Group, Inc., sold 17,615 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Philip Astley-Sparke, Executive Chairman of Replimune Group, sold 37,928 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Director Robert Coffin sold 11,464 shares of Replimune Group, Inc. to cover tax withholding obligations related to the vesting of restricted stock units.

Replimune Group, Inc.'s CEO, Sushil Patel, sold 20,194 shares of common stock on May 16, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Konstantinos Xynos, Chief Medical Officer of Replimune Group, sold 6,367 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Veleka Peeples-Dyer, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2024.

CEO of Replimune Group, Sushil Patel, reports acquisition of shares and stock options in the company.

Director Paolo Pucci reports acquisition of stock options in Replimune Group, Inc.

Konstantinos Xynos, Chief Medical Officer of Replimune Group, reports acquiring shares through restricted stock units and stock options.

Kapil Dhingra, a director of Replimune Group, Inc., reported the acquisition of stock options exercisable for 32,000 shares of common stock on April 1, 2024.

Emily Hill, CFO of Replimune Group, reports acquisition of stock options and restricted stock units.

Christopher Sarchi, Chief Commercial Officer of Replimune Group, reports acquisition of stock and stock options.

Joseph P. Slattery, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2024.

Director Dieter Weinand of Replimune Group, Inc. reports acquiring 32,000 stock options on April 1, 2024, exercisable at $7.73, according to a Form 4 filing.

Christy J. Oliger, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2024.

Director Hyam Levitsky acquired 32,000 stock options in Replimune Group, Inc. on April 1, 2024, according to a recent SEC filing.

Andrew Schwendenman, Chief Accounting Officer of Replimune Group, reports the acquisition of stock options and vesting of restricted stock units (RSUs) in a recent SEC filing.